Similar articles

• Drotrecogin alfa (activated) in South African private hospital ICUs.

  Hodgson RE, Williams PG, Foden AP, Grolman D. Hodgson RE, et al. S Afr Med J. 2003 Jul;93(7):474-5. S Afr Med J. 2003. PMID: 12939910 No abstract available.
• Impact of drotrecogin alfa (activated) on resource use and implications for reimbursement.

  Dasta JF, Cooper LM. Dasta JF, et al. Pharmacotherapy. 2002 Dec;22(12 Pt 2):216S-222S. doi: 10.1592/phco.22.18.216s.33703. Pharmacotherapy. 2002. PMID: 12492228 Review.
• The story of drotrecogin alfa - evidence-based or evidence-biased?

  Wiseman R, Blockman M. Wiseman R, et al. S Afr Med J. 2011 Dec 13;102(1):8. S Afr Med J. 2011. PMID: 22273122 No abstract available.
• Long-term cost effectiveness of drotrecogin alfa (activated): an unanswered question.

  Banks SM, Gerstenberger E, Eichacker PQ, Natanson C. Banks SM, et al. Crit Care Med. 2003 Jan;31(1):308-9. doi: 10.1097/00003246-200301000-00050. Crit Care Med. 2003. PMID: 12545035 No abstract available.
• Drotrecogin alfa (activated) for severe sepsis.

  [No authors listed] [No authors listed] Drug Ther Bull. 2006 Jan;44(1):5-8. doi: 10.1136/dtb.2006.4415. Drug Ther Bull. 2006. PMID: 16425899 Review.